Thelansis

  Lung cancer continues to be the primary cause of cancer-related mortality, with approximately 13% of lung cancer cases being diagnosed as small cell lung cancer (SCLC). Despite its sensitivity to chemotherapy and radiation therapy, nearly all SCLC patients experience disease relapse or progression. Topotecan, a water-soluble, semisynthetic derivative of camptothecin, stands as the sole FDA-approved second-line chemotherapy for relapsed SCLC, known for its specific inhibition of topoisomerase. In contrast, Amrubicin, also a topoisomerase inhibitor II, has demonstrated superior antitumor activity to topotecan, albeit it is currently approved solely in Japan. While multiagent chemotherapy has historically shown higher response rates in relapsed SCLC compared to single-agent chemotherapy, it often comes with increased toxicities. Given the frequent occurrence of relapses in SCLC patients, systemic therapy following first-line treatment failure remains a vital component of the treat...